scholarly journals Invasive Salmonellosis by the Very RareSalmonella choleraesuisin a Returning Traveler on a Tumor Necrosis Factor-αInhibitor

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Uzoamaka A. Eke ◽  
Harry Conte ◽  
Paula Anderson ◽  
Robert W. Lyons
Keyword(s):  
United States ◽  
Tumor Necrosis Factor ◽  
Dominican Republic ◽  
Tumor Necrosis ◽  
The United States ◽  
The State ◽  
Salmonella Choleraesuis ◽  
Human Source ◽  
Necrosis Factor

Salmonella choleraesuisis one of the least commonly reported nontyphoidal salmonellae in the United States, accounting for only 0.08% and ranking lower than 20th place among all human source salmonellosis reported to the CDC in 2009. In the state of Connecticut, only 12 cases have been reported since 1998 and our case is the only case since 2008. We report a case of invasive Salmonellosis caused bySalmonella choleraesuisin a patient on an antitumor necrosis factor-αagent (adalimumab) who recently returned from a trip to the Dominican Republic.

Enbrel: The Sting of Success

2017 ◽  
pp. 1-20
Author(s):  
Alicia Löffler ◽  
Geetha P. Krishnan
Keyword(s):  
Rheumatoid Arthritis ◽  
United States ◽  
Decision Making ◽  
Tumor Necrosis Factor ◽  
Effective Treatment ◽  
Tumor Necrosis ◽  
The United States ◽  
Decision Making Process ◽  
Biotechnology Company ◽  
Necrosis Factor

Immunex, a small Seattle biotechnology company, stumbles into a hugely successful and groundbreaking product. Enbrel, a tumor necrosis factor, is immediately recognized as the most effective treatment for rheumatoid arthritis–a $300 billion market in the United States. After almost 20 years of unprofitability, Enbrel is a lifesaver for Immunex. But it could also become the company's worst nightmare. Immunex, after years of being cash starved, has not been able to build production capabilities to satisfy the sudden and massive demand for its drug.To illustrate the decision-making process concerning how and when to build commercialization capabilities in a small biotechnology company. Also, to explore options for reacting to an unexpected demand in a hypercompetitive market.

Sign in / Sign up

Export Citation Format

Share Document